12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Eliquis apixaban regulatory update

EMA's CHMP issued a positive opinion for Eliquis apixaban from Bristol-Myers Squibb and partner Pfizer to expand the indication of the 2.5 mg dose strength to include the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (AF) with >=1 risk factors and...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >